These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 37523078)
1. MMP11 and MMP17 are potential biomarkers for uterine corpus endometrial carcinoma prognosis. Zhang Y; Wang J; Fan Y; Lang F; Fu F; Liu Q Clin Transl Oncol; 2024 Mar; 26(3):653-663. PubMed ID: 37523078 [TBL] [Abstract][Full Text] [Related]
2. LINC01589 serves as a potential tumor-suppressor and immune-related biomarker in endometrial cancer: A review. Chen R; An J; Wang Y; Yang L; Lin Q; Wang Y Medicine (Baltimore); 2023 Apr; 102(15):e33536. PubMed ID: 37058060 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of zinc finger DHHC-type containing 1 is associated with poor prognosis and cancer cell growth and metastasis in uterine corpus endometrial carcinoma. Jiang N; Li D; Han Y; Luo ZG; Liu LB Aging (Albany NY); 2024 Jun; 16(11):9784-9812. PubMed ID: 38848146 [TBL] [Abstract][Full Text] [Related]
4. A Five-microRNA Signature as Risk Stratification System in Uterine Corpus Endometrial Carcinoma. Chen Z; Huang X; Lv Y; Fang Y; Pan L; Gan Z; Huang Z; Wei W Comb Chem High Throughput Screen; 2021; 24(2):187-194. PubMed ID: 32748742 [TBL] [Abstract][Full Text] [Related]
5. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis. Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189 [TBL] [Abstract][Full Text] [Related]
6. Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118 [TBL] [Abstract][Full Text] [Related]
7. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma. Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290 [TBL] [Abstract][Full Text] [Related]
8. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma. Wang Z; Xing L; Huang Y; Han P Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126 [TBL] [Abstract][Full Text] [Related]
9. Construction of prediction model for prognosis of uterine corpus endometrial carcinoma based on pyroptosis gene. Zhang C; Bai J; Yang Y; Wang X; Liu W; Hou S; Ai Z; Xia Q; Shao L Clin Transl Oncol; 2023 May; 25(5):1413-1424. PubMed ID: 36520385 [TBL] [Abstract][Full Text] [Related]
10. [Dysregulation of MAD2L1/CAMK2A/PTTG1 Gene Cluster Maintains the Stemness Characteristics of Uterine Corpus Endometrial Carcinoma]. Zheng J; Zhang YW; Pan ZF Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Oct; 43(5):685-695. PubMed ID: 34728029 [TBL] [Abstract][Full Text] [Related]
11. MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma. Chen J; Wu S; Wang J; Han C; Zhao L; He K; Jia Y; Cui M J Cell Mol Med; 2023 Jun; 27(12):1708-1724. PubMed ID: 37246638 [TBL] [Abstract][Full Text] [Related]
12. RNA modification regulator DDC in endometrial cancer affects the tumor microenvironment and patient prognosis. Zhao H; Shi C; Zhao G; Liu J; Wang X; Liang J; Li F Sci Rep; 2023 Oct; 13(1):18057. PubMed ID: 37872211 [TBL] [Abstract][Full Text] [Related]
13. TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy. Zhu X; Yuan Z; Cheng S; Wang H; Liao Y; Zhou D; Wu Z World J Surg Oncol; 2022 Oct; 20(1):336. PubMed ID: 36207751 [TBL] [Abstract][Full Text] [Related]
14. Increased expression of MMP17 predicts poor clinical outcomes in epithelial ovarian cancer patients. Xiao C; Wang Y; Cheng Q; Fan Y Medicine (Baltimore); 2022 Aug; 101(34):e30279. PubMed ID: 36042626 [TBL] [Abstract][Full Text] [Related]
15. Signal transducer and activator of transcription family is a prognostic marker associated with immune infiltration in endometrial cancer. Zhou XY; Dai HY; Zhang H; Zhu JL; Hu H J Clin Lab Anal; 2022 Apr; 36(4):e24315. PubMed ID: 35244291 [TBL] [Abstract][Full Text] [Related]
16. Identification and validation of oxeiptosis-associated lncRNAs and prognosis-related signature genes to predict the immune status in uterine corpus endometrial carcinoma. Niu L; Wu Z Aging (Albany NY); 2023 May; 15(10):4236-4252. PubMed ID: 37211398 [TBL] [Abstract][Full Text] [Related]
17. Human Rathbun LA; Magliocco AM; Bamezai AK Oncotarget; 2023 May; 14():426-437. PubMed ID: 37141412 [TBL] [Abstract][Full Text] [Related]
18. m Fang F; Wang P; Huang H; Ye M; Liu X; Li Q BMC Cancer; 2022 Dec; 22(1):1364. PubMed ID: 36581816 [TBL] [Abstract][Full Text] [Related]
19. LHX1 as a potential biomarker regulates EMT induction and cellular behaviors in uterine corpus endometrial carcinoma. Tian Y; Wen F; Wang S; Lv N Clinics (Sao Paulo); 2022; 77():100103. PubMed ID: 36116266 [TBL] [Abstract][Full Text] [Related]
20. miR-149-3p Is a Potential Prognosis Biomarker and Correlated with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma. Lu X; Jing L; Liu S; Wang H; Chen B Int J Endocrinol; 2022; 2022():5006123. PubMed ID: 35719192 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]